Specific Antiviral Drugs For COVID 19 Global Market Report 2025

The specific antiviral drugs for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $28.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. Key drivers in the forecast period include greater emphasis on pandemic preparedness, expansion of clinical trial activities, heightened need for effective treatment options, increasing circulation of COVID-19 variants, and rising acceptance of orally administered antiviral medications. Notable trends expected to shape the market include the development of broad-spectrum antiviral solutions, use of AI technologies in drug development, progress in personalized antiviral treatment methods, innovations in combination therapies, and the application of genomic insights to counter viral mutations.

The rising number of COVID-19 cases is expected to propel the growth of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals who tested positive for the SARS-CoV-2 virus, which causes COVID-19. The increase in cases is due to the emergence of new variants that spread more easily and can partially evade immunity from vaccines or past infections. Specific antiviral drugs for COVID-19 help reduce the severity and duration of the illness, improving patient outcomes and lowering the overall burden of COVID-19 cases. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, on average, COVID-19 deaths that included additional causes of death had 4.5 contributing conditions listed in 2022, compared to 4.2 in 2021. Therefore, the rising number of COVID-19 cases drives the growth of the specific antiviral drugs for the COVID-19 market.

Major companies operating in the specific antiviral drugs for the COVID-19 market are focusing on developing innovative therapies, such as oral antiviral therapies, to enhance treatment accessibility and effectiveness. Oral antiviral therapies are medications taken by mouth to inhibit the replication of viruses like COVID-19, offering a convenient and effective treatment option. For instance, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral drug Molnupiravir under the brand name Molnulup to treat high-risk adult patients with COVID-19. This oral medication is intended for adults with mild to moderate COVID-19 who are at risk of developing severe illness. Molnupiravir works by inhibiting the replication of the SARS-CoV-2 virus, thereby helping to lower the viral load and reduce the severity of the disease. It is most effective when started within five days of symptom onset and is especially beneficial for individuals with comorbid conditions such as obesity, advanced age, diabetes, or cardiovascular disease.

In July 2024, GSK plc, a UK-based pharmaceutical company, collaborated with CureVac to develop and commercialize next-generation mRNA vaccines for COVID-19 and influenza. This collaboration aims to develop and commercialize innovative mRNA vaccines for influenza and COVID-19 to improve global public health outcomes. CureVac N.V. is a Germany-based company that develops therapies based on messenger RNA (mRNA) technology.

Major players in the specific antiviral drugs for COVID-19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc.

North America was the largest region in the specific antiviral drugs for COVID-19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in specific antiviral drugs for COVID-19 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the specific antiviral drugs for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Specific antiviral drugs for COVID-19 are therapeutics specifically developed to target and disrupt the replication or activity of the SARS-CoV-2 virus, the causative agent of COVID-19. These medications function by interfering with vital viral processes such as entry into host cells, replication, or assembly, thereby helping to lessen the severity and duration of the illness.

These antiviral drugs are available in both tablet and injectable formulations. Tablets are compressed solid dosage forms containing a fixed amount of active pharmaceutical ingredients along with excipients, typically in a flat or oval shape. These medications are prescribed for use in hospitalized patients, individuals receiving outpatient care, as well as for preventive purposes. They fall into various pharmacological categories, including nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies, and are administered via oral, intravenous, subcutaneous, or inhalation routes. The distribution channels for these drugs include hospital pharmacies, retail pharmacies, and other pharmaceutical outlets.

The specific antiviral drugs for COVID-19 market size has grown rapidly in recent years. It will grow from $13.0 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. Growth during the historic period was driven by factors such as the surge in hospital admissions due to severe infections, increased governmental investment in antiviral development, rising demand for targeted treatment solutions over generic alternatives, heightened awareness of the benefits of early antiviral administration, and enhanced collaboration among pharmaceutical firms.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.